leisure time -WSS

leisure time

author：Wikipedia 2025-09-30 17:27:56 - browse：11

STAT Q&A — Paul Matteis (right), in 2017 with then-colleagues Seamus Fernandez (far left) Geoffrey Porges. Alex Hogan/STAT

NEW YORK — Is biotech having a renaissance in neuroscience? Can we solve the placebo effect? And what’s going to happen next year?

Paul Matteis, co-head of biotech research at Stifel, sat down with STAT at the firm’s annual health care conference here to field those questions and opine on how management teams can walk the delicate balance between hype and sandbagging. This transcript has been edited for length and clarity.

One thing I’ve been hearing lately is that biotech has entered a sort of renaissance in neuroscience. Do you agree with that?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Astellas still sees hope in its gene therapy after four deaths

hotspot

WSS

Weight loss drug costs may need more research, senator suggests

PBM reforms clear House panel

Surge of respiratory disease in China has likely explanation

{$content}

U.K. considers world's first use of meningitis vaccine to address gonorrhea

Congress must reauthorize a committee to support older Americans

hotspot

leisure time

entertainment

Hollywood unions extend contract negotiations for actors

Medicare proceeds with plan to claw back hospital funds

After affirmative action ruling, medical educators look to 'holistic review'

Surge of respiratory disease in China has likely explanation

The cancer drug shortage isn’t new — and neither are the solutions

Lung cancer screening guidelines updated for cigarette smokers

United colonoscopy coverage change 'may cost lives,' doctors say

The health care issue Democrats can’t solve: hospital reform

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Surge of respiratory disease in China has likely explanation

Wikipedia

Anthos stroke drug appears safer than common blood thinner

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

What is microchimerism and how does it affect maternal health?

Humans aren't the only ones with an imagination. Rats have it too

Readout LOUD podcast: The Sarepta saga, decoding biotech hype

FDA's Woodcock to retire early next year

entertainment

explore

hotspot

leisure time